How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,870 results for

Nocturia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Desmopressin for treating nocturia in men. (PubMed)

Desmopressin for treating nocturia in men. Nocturia is the bothersome symptom of awakening one or more times per night to void. Desmopressin is a commonly used medication for treating nocturia.To assess the effects of desmopressin as compared to other interventions in the treatment of nocturia in men.We performed a comprehensive search of medical literature with no restrictions on the language of publication or publication status. The date of the latest search of all databases was August 2017 (...) .We included randomized or quasi-randomized trials. Inclusion criteria were men with nocturia defined as one or more voids per night. Trials of children, adults with primary or secondary enuresis or underlying distinct disorders were excluded.Two review authors independently classified studies and abstracted data from the included studies. We performed statistical analyses using a random-effects model and interpreted data according to the Cochrane Handbook for Systematic Reviews

Full Text available with Trip Pro

2017 Cochrane

2. A case study: Effects of foot reflexotherapy on ADHD symptoms and enuresis nocturia in a child with ADHD and enuresis nocturia. (PubMed)

A case study: Effects of foot reflexotherapy on ADHD symptoms and enuresis nocturia in a child with ADHD and enuresis nocturia. Symptoms of Attention-Deficit Hyperactivity Disorder (ADHD) can occur in association with enuresis nocturia. Alternative therapies may be effective in addressing the maladies of children with ADHD comorbidities. The purpose of this study was to investigate the effects of foot reflexotherapy in a child with ADHD and enuresis nocturia.The patient was an 8-year-old child (...) with ADHD and enuresis nocturia. Pre- and post-tests for ADHD were completed using Vanderbilt ADHD Diagnostic Teacher Rating Scale. The subject was treated with foot reflexotherapy for 20-min per session twice per week for a period of 8 weeks.The child showed improvement in ADHD symptoms and his enuresis nocturia disappeared completely after foot reflexotherapy.Foot reflexotherapy was effective in improving inattention, hyperactivity in the child with ADHD. The results of this novel study suggest

2018 Complementary Therapies in Clinical Practice

3. Diagnosis and management of nocturia in current clinical practice: who are nocturia patients, and how do we treat them? (PubMed)

Diagnosis and management of nocturia in current clinical practice: who are nocturia patients, and how do we treat them? To characterize the current evaluation, and efficacy of treatments in patients with the primary complaint of nocturia.A retrospective chart review was performed of new patient encounters seen in a tertiary urology practice from May 2010 to September 2016 with the primary diagnosis of nocturia (ICD-9 788.43 and ICD-10 R35.1).595 patients were identified. 403 met inclusion (...) criteria. The median patient reported that nocturia episodes were 4 (1-20). 192 patients (48%) reported previous treatment for nocturia. After the index visit, a bladder diary (BD) was utilized in 50% of patients, with a 62% (n = 124) completion rate at follow-up visit. On BD analysis, the most common etiologies of nocturia were nocturnal polyuria 76% (n = 90) and overactive bladder in 21% (n = 26). Patient reported improvement with therapy after BD completion was 46% (n = 34), similar to patients

2018 World journal of urology

4. The evaluation of nocturia in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and the analysis of the curative effect after medical or placebo therapy for nocturia: a randomized placebo-controlled study. (PubMed)

The evaluation of nocturia in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and the analysis of the curative effect after medical or placebo therapy for nocturia: a randomized placebo-controlled study. To study nocturia in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) after medical or placebo treatment.Patients with LUTS suggestive of BPH from several community clinics were included. Patients completed (...) , prostate volume (PV), I-PSS, etc. RESULTS: The average I-PSS score was 20.3, storage symptom score was 11.7, voiding symptom score was 8.6, quality of life (QoL) score was 3.7, PV was 40.4 ± 19.4 ml, and nocturnal urine volume (NUV) was 845.7 ± 339.0 ml. The mean frequency of nocturia was 2.3 ± 1.1 per day, and 94% of the patients had a nocturia frequency of more than two times per day. Of these patients, 76.5% had NP. A significant correlation was found between NUV and the amount of water intake

2018 BMC Urology Controlled trial quality: uncertain

5. Development of a multivariate prediction model for nocturia, based on urinary tract etiologies

Development of a multivariate prediction model for nocturia, based on urinary tract etiologies The main objective of our study was to determine which combination of modifiable and non-modifiable parameters that could discriminate patients with nocturia from those without nocturia. This was a post-hoc analysis of 3 prospective, observational studies conducted in Ghent University. Participants completed frequency volume chart (FVC) to compare characteristics between patients with and without (...) nocturia.This was a post hoc analysis of three prospective, observational studies conducted in Ghent University. Participants completed frequency volume chart (FVC) to compare characteristics between adults with and without nocturia. Study 1: adults with and without nocturia (n = 148); Study 2: patients ≥65 years with and without nocturnal LUTS (n = 54); Study 3: menopausal women before and after hormone replacement therapy (n = 43). All eligible patients (n = 183) completed a FVC during 24 hours (n = 13

Full Text available with Trip Pro

2019 EvidenceUpdates

6. Influence of Daytime or Nighttime Dosing with Solifenacin for Overactive Bladder with Nocturia: Impact on Nocturia and Sleep Quality (PubMed)

Influence of Daytime or Nighttime Dosing with Solifenacin for Overactive Bladder with Nocturia: Impact on Nocturia and Sleep Quality We compared changes in nocturia and sleep-related parameters between daytime and nighttime solifenacin dosing in patents with overactive bladder (OAB) and nocturia. We comparatively analyzed the data of a 12-week prospective, open-label, multicenter, randomized study. All 127 patients who presented to 5 centers in Korea for the treatment of OAB with nocturia (...) sex, age, body mass index (BMI), total AIS, IPSS, and OABSS, did not differ between the 2 groups. Total IPSS, OABSS, and total AIS significantly improved after solifenacin administration regardless of timing (P < 0.001). After solifenacin administration, the number of nocturia episodes decreased in the group 1 and 2 (P < 0.001). There were no significant intergroup differences in changes in AIS, IPSS, OABSS, and number of nocturia episodes 12 weeks after solifenacin administration. Treating OAB

Full Text available with Trip Pro

2017 Journal of Korean medical science Controlled trial quality: uncertain

7. Variations of Nighttime and Daytime Bladder Capacity in Patients with Nocturia: Implication for Diagnosis and Treatment. (PubMed)

Variations of Nighttime and Daytime Bladder Capacity in Patients with Nocturia: Implication for Diagnosis and Treatment. We subtyped patients with nocturia according to daily variations in urine production and bladder capacity.Patients with 1 or more nocturia episodes per day were prospectively enrolled in this study. Post-void residual urine was collected and a 3-day frequency-volume chart was created. Nocturnal polyuria and bladder capacity were calculated for each patient. Reduced bladder (...) of nocturia episodes (3, IQR 2-3). Patients with normal bladder capacity but with nocturnal polyuria had significantly larger mean and maximum bladder capacity at night (p = 0.033 and 0.016, respectively). In patients with reduced bladder capacity and no nocturnal polyuria we observed no significant variation in bladder capacity during the day vs the night. On multivariable analysis the body mass index (OR 1.28 per unit, 95% CI 1.04-1.58, p = 0.019) and severe nocturia (OR 6.26, 95% CI 1.71-22.92, p

2019 Journal of Urology

8. Liquid chromatography-mass spectrometry identification of serum biomarkers for nocturia in aged men. (PubMed)

Liquid chromatography-mass spectrometry identification of serum biomarkers for nocturia in aged men. We aimed to investigate the association between nocturia and serum metabolites identified using metabolomics analysis.This study enrolled 66 men aged 65-80 years, recruited from the outpatient department of a university hospital. The participants were stratified as follows: Nocturia group [45 men with any total international prostate symptom score (IPSS) and an average of 3 nights ≥ 1.5 (...) micturitions/night] and Control group (21 men with total IPSS < 8 and an average of 3 nights < 1.5 micturitions/night). The 24-h frequency-volume chart, IPSS, and Quality-of-Life questionnaire were used to evaluate micturition behavior. Serum metabolite profiles were obtained using liquid chromatography-mass spectrometry (LC-MS)-based metabolomics analysis and compared between the two groups using the unpaired t test. The relationship between serum metabolites and nocturia was determined using

2019 World journal of urology

9. Accuracy of a "Single Question Nocturia Score" compared to the "International Prostate Symptoms Score" in the evaluation of lower urinary tract symptoms in benign prostatic hyperplasia: A study performed at Ndola Teaching Hospital, Ndola, Zambia. (PubMed)

Accuracy of a "Single Question Nocturia Score" compared to the "International Prostate Symptoms Score" in the evaluation of lower urinary tract symptoms in benign prostatic hyperplasia: A study performed at Ndola Teaching Hospital, Ndola, Zambia. The International Prostate Symptom Score (IPSS) is a useful tool approved by the World Health Organisation and the American Urological Association to measure the severity of lower urinary tract symptoms (LUTS). Although commonly used in urological (...) practice, the IPSS has faced many challenges in terms of its usage in developing countries. In our setting, most patients presenting with this condition are elderly patients with a low literacy level. Given this background, the IPSS could be time consuming and difficult to administer to such patients and it may lead to additional costs to the services.The objective of this study was to compare the accuracy of a Single Question Nocturia Score (SQNS) with the IPSS in evaluation of lower urinary tracts

Full Text available with Trip Pro

2018 PLoS ONE

10. The discrepancy between European Association of Urology (EAU) guidelines and daily practice in the evaluation and management of nocturia: results of a Dutch survey. (PubMed)

The discrepancy between European Association of Urology (EAU) guidelines and daily practice in the evaluation and management of nocturia: results of a Dutch survey. In addition to the evaluation of voiding symptoms, in the evaluation of patients with nocturia, one should also consider other related causes such as sleep disorders, obstructive sleep apnoea (OSAS), diabetes and heart failure. In this study, we have aimed to assess the current knowledge and implementation of the EAU guidelines (...) regarding nocturia in common urological practice in the Netherlands.In a national cross-sectional survey distributed among 450 urologists and urology residents in the Netherlands, the implementation of the recommendations of the European Association of Urology (EAU) guidelines on nocturia evaluation and management was studied.This survey revealed that only some aspects of the EAU guidelines are applied in the daily clinical practice and that some important parts are not. For example, only a minority

2019 World journal of urology

11. Future Considerations in Nocturia and Nocturnal Polyuria. (PubMed)

Future Considerations in Nocturia and Nocturnal Polyuria. Nocturnal polyuria (NP), the most common etiology of nocturia, can be caused by various medical conditions, including cardiovascular disease, obstructive sleep apnea, renal tubular dysfunction, as well as medications (e.g. diuretics) and/or behavioral patterns. NP in the absence of underlying medical conditions has been described as nocturnal polyuria syndrome (NPS) and is thought be the result of impaired circadian release of endogenous (...) arginine vasopressin (AVP). Desmopressin, a synthetic AVP analog, has been shown to be an effective replacement therapy in adults with nocturia due to NP. Further studies on the subset of patients with NPS are warranted to maximize benefit from antidiuretic treatment. In addition, a connection between the pathophysiological mechanisms underlying NP and essential hypertension has been suggested, and hypertension has been shown to be a significant risk factor for nocturia, while an association between NP

2019 Urology

12. Urinary Incontinence and Nocturia in Older Men: Associations with Body Mass, Composition, and Strength in the Health, Aging, and Body Composition Study. (PubMed)

Urinary Incontinence and Nocturia in Older Men: Associations with Body Mass, Composition, and Strength in the Health, Aging, and Body Composition Study. Among younger men, lower body mass is associated with fewer urinary symptoms, including incontinence and nocturia. However, lower body mass may have different implications for older men due to age-associated muscle atrophy and decreased strength.We conducted a prospective analysis of community-dwelling men, aged 70 to 79, in the multicenter (...) Health, Aging, and Body Composition Study who underwent measurement of body mass (physical examination), composition (dual x-ray absorptiometry), and strength (grip and lower leg dynamometry). Associations with prevalent incontinence and nocturia (from structured questionnaires), as well as concurrent changes in urinary symptoms over 3 years was evaluated using multivariate logistic regression.Of the 1,298 men analyzed, 22% reported incontinence and 52% reported nocturia at baseline. Higher body mass

2019 Journal of Urology

13. Effects of two nonpharmacological treatments on the sleep quality of women with nocturia: a randomized controlled clinical trial. (PubMed)

Effects of two nonpharmacological treatments on the sleep quality of women with nocturia: a randomized controlled clinical trial. The objective was to check the effects of two nonpharmacological treatments on the sleep quality of women with nocturia.A randomized controlled clinical trial in which 40 women with nocturia were randomized into two groups; one was subjected to tibial nerve stimulation (GTNS) and the other received pelvic floor muscle training associated with behavioral therapy (...) to 7 ± 0.94, p = 0.002; GPFMT from 8 ± 0.80 to 5 ± 0.94, p < 0.001) and the sleep/energy domain of the KHQ (GTNS from 66.66 ± 9.03 to 16.66 ± 7.20, p = 0.002; GPFMT from 66.66 ± 9.30 to 0.00 ± 7.26, p = 0.001).Both nonpharmacological treatments proposed (TNS or PFMT) were equally able to improve quality of sleep of women with nocturia.

2019 International urogynecology journal Controlled trial quality: uncertain

14. Impact of nocturia on patients' health-related quality of life and healthcare resource utilisation compared with OAB and BPH: Results from an observational survey in European and American patients. (PubMed)

Impact of nocturia on patients' health-related quality of life and healthcare resource utilisation compared with OAB and BPH: Results from an observational survey in European and American patients. To evaluate the impact of nocturia on patients' quality of life and healthcare resource utilisation (HRU) compared with overactive bladder (OAB) and benign prostatic hyperplasia (BPH).Data were drawn from a multinational (France, Germany, Spain, UK and US) survey of physician and patient-reported (...) outcomes. The patient groups of interests were those diagnosed with only nocturia, with only OAB, and with only BPH. Health-related quality of life (HRQoL) and productivity measures were derived from the EuroQoL-5D, OAB-q and the Work Productivity and Activity Impairment Questionnaire (WPAI). Measures of HRU included lower urinary tract symptoms (LUTS)-relevant surgeries, hospitalisations, current use of pads and related physician visits. Bivariate and multivariate regression analyses were used

2019 International journal of clinical practice

15. Re: UWIN (Urgency, Weak Stream, Incomplete Void, Nocturia) Score for Assessment of Lower Urinary Tract Symptoms: Could it Replace the American Urology Association Symptom Index Score? An Open Label Randomized Cross Over Trial. (PubMed)

Re: UWIN (Urgency, Weak Stream, Incomplete Void, Nocturia) Score for Assessment of Lower Urinary Tract Symptoms: Could it Replace the American Urology Association Symptom Index Score? An Open Label Randomized Cross Over Trial. 30652995 2019 04 16 2019 04 16 1527-3792 201 4 2019 04 The Journal of urology J. Urol. Re: UWIN (Urgency, Weak Stream, Incomplete Void, Nocturia) Score for Assessment of Lower Urinary Tract Symptoms: Could it Replace the American Urology Association Symptom Index Score (...) ? An Open Label Randomized Cross Over Trial. 640-641 10.1097/01.JU.0000553304.08866.65 Kaplan Steven A SA eng Journal Article Comment United States J Urol 0376374 0022-5347 AIM IM Low Urin Tract Symptoms. 2018 May;10(2):131-134 28256100 Cross-Over Studies Humans Lower Urinary Tract Symptoms Nocturia Rivers United States Urination Disorders Urology 2019 1 18 6 0 2019 4 17 6 0 2019 1 18 6 0 ppublish 30652995 10.1097/01.JU.0000553304.08866.65

2019 The Journal of urology Controlled trial quality: uncertain

16. Re: Novel Immediate/Sustained-Release Formulation of Acetaminophen-Ibuprofen Combination (Paxerol®) for Severe Nocturia Associated with Overactive Bladder: A Multi-Center, Randomized, Double Blinded, Placebo-Controlled, 4-Arm Trial. (PubMed)

Re: Novel Immediate/Sustained-Release Formulation of Acetaminophen-Ibuprofen Combination (Paxerol®) for Severe Nocturia Associated with Overactive Bladder: A Multi-Center, Randomized, Double Blinded, Placebo-Controlled, 4-Arm Trial. 31075063 2019 07 29 2019 07 29 1527-3792 202 2 2019 08 The Journal of urology J. Urol. Re: Novel Immediate/Sustained-Release Formulation of Acetaminophen-Ibuprofen Combination (Paxerol®) for Severe Nocturia Associated with Overactive Bladder: A Multi-Center (...) , Randomized, Double Blinded, Placebo-Controlled, 4-Arm Trial. 217-218 10.1097/01.JU.0000559741.76277.47 Wein Alan J AJ eng Journal Article Comment 2019 07 08 United States J Urol 0376374 0022-5347 0 Delayed-Action Preparations 362O9ITL9D Acetaminophen WK2XYI10QM Ibuprofen Neurourol Urodyn. 2019 Feb;38(2):740-748 30592553 Acetaminophen Delayed-Action Preparations Double-Blind Method Humans Ibuprofen Nocturia Urinary Bladder, Overactive 2019 5 11 6 0 2019 7 30 6 0 2019 5 11 6 0 ppublish 31075063 10.1097/01

2019 The Journal of urology Controlled trial quality: predicted high

17. Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group devel (PubMed)

Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group devel This study assessed the efficacy and safety of desmopressin orally disintegrating tablets (ODTs) in Japanese males (50 and 25 μg) and females (25 μg) with nocturia due to nocturnal polyuria (NP). Two Phase 3 randomized double-blind placebo (...) -controlled studies of 342 males and 190 females with nocturia due to NP were conducted. The primary endpoint was change from baseline in mean number of nocturnal voids. In addition, time to first awakening to void, nocturnal urine volume, NP index (NPI), and quality of life were assessed during a 12-week treatment period. In males, 50 and 25 μg desmopressin ODTs significantly reduced the number of nocturnal voids by -1.21 (P < .0001) and - 0.96 (P = .0143), respectively, and significantly prolonged

2019 Lower urinary tract symptoms Controlled trial quality: uncertain

18. Low-dose Desmopressin Orally Disintegrating Tablet: Suggested Clinically Meaningful Benefit in Patients with Nocturia Due to Nocturnal Polyuria. (PubMed)

Low-dose Desmopressin Orally Disintegrating Tablet: Suggested Clinically Meaningful Benefit in Patients with Nocturia Due to Nocturnal Polyuria. Clinical benefit has not been evaluated much in patients with nocturia.To assess the clinical benefit of desmopressin orally disintegrating tablet (ODT) in women (25μg) and men (50μg) with nocturia due to nocturnal polyuria (NP).Patients with NP from two randomised, placebo-controlled trials in men (CS41) and women (CS40) with two or more nocturnal

2018 European urology focus Controlled trial quality: uncertain

19. Nocdurna (desmopressin) - for symptomatic treatment of nocturia

Nocdurna (desmopressin) - for symptomatic treatment of nocturia Nocdurna® (desmopressin) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Nocdurna® (desmopressin) Conclusion Nocdurna was marketed in Denmark in August 2016 for symptomatic treatment of nocturia caused by idiopathic nocturnal polyuria in adults. Nocdurna differs from existing desmopressin products by its lower strengths of respectively 25 µg and 50 µg per tablet, enabling a lower dose (...) justifies the adverse reactions. It is IRF's overall assessment that Nocdurna treatment cannot be recommended to treat nocturia caused by idiopathic nocturnal polyuria in adults because the effect is too modest compared to the price and adverse reactions. The treatment could be considered for patients who have not responded adequately to lifestyle intervention regarding fluid intake and urination in the evening hours, but if no clinically relevant improvement is seen within approx. 1 month, it should

2017 Danish Pharmacotherapy Reviews

20. Nocturia Is Associated with Slipping and Falling. (PubMed)

Nocturia Is Associated with Slipping and Falling. Several reports have demonstrated associations between falls and nocturia in the elderly. However, little information is available regarding other age groups. This study evaluated the relationship between the frequency of nocturia and falls in men using a large, population-based survey in Korea, and the results were adjusted for various confounding factors. Data from a 2011 Korean community health survey (KCHS) were retrieved for 92,660 men aged (...) 19 to 103 years. Information regarding the history of slips or falls in the past year was collected. The frequency of nocturia was classified as 0, 1, 2, 3, 4, and ≥ 5 instances a night. Walking during the day, education, income, body mass index (BMI), smoking, alcohol consumption, sleep time, stress level and medical histories of hypertension, diabetes mellitus, hyperlipidemia, cerebral stroke, angina or myocardial infarction, arthritis, and osteoporosis were adjusted using multiple logistic

Full Text available with Trip Pro

2017 PLoS ONE

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>